Chugai's Bispecific Antibody "Emicizumab" Global Phase III Data in Patients with Haemophilia A with Inhibitors Published in The New England Journal of Medicine Online
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the data from HAVEN 1 study (NCT02622321) was published in the online version of The New England Journal of Medicine (NEJM) . This global phase III study examined Chugai’s bispecific antibody emicizumab in adults and adolescents 12 years of age or older with haemophilia A with inhibitors. Results of HAVEN 1 study and the interim analysis of HAVEN 2 study (NCT02795767), a global phase III study of emicizumab in paediatric patients with haemophilia A with inhibitors, are presented today at the 26th International Society on Thrombosis and Haemostasis (ISTH) Meeting in Berlin.
“HAVEN 1 study is the first global phase III study for emicizumab. This important data provides the body of evidence for the upcoming new drug application,” said Chugai’s President & COO, Tatsuro Kosaka. “The interim analysis of HAVEN 2 study showed that emicizumab offers benefit for children as well. Chugai is committed to provide a new treatment option as soon as possible for the disease which may severely affect patients' life.”
Chugai is currently preparing to file the new drug application in Japan for emicizumab based on the data of HAVEN 1 study and the interim analysis of HAVEN 2 study. These data have been filed with the US Food and Drug Administration (FDA) and the European Medicines Agency by Roche. Emicizumab was designated as a Breakthrough Therapy by the FDA for the prophylactic treatment of people who are 12 years or older with haemophilia A with factor VIII inhibitor in September 2015.
Chugai Pharmaceutical Co., Ltd.
Media Relations Group, Corporate Communications Dept.,
For US media
Chugai Pharma USA Inc.
For European media
Chugai Pharma France SAS
For Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou, Osamu Kagawa
Chugai Pharmaceutical Co., Ltd.
Investor Relations Group, Corporate Communications Dept.,
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
SOFTOMOTIVE22.6.2018 17:15 | pressemeddelelse
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA
TX-ASCEND-PERFORMANCE22.6.2018 16:02 | pressemeddelelse
Ascend Performance Materials Announces Price Increase for Intermediate Materials
DELTICOM-AG/MOTO-TYRES.C22.6.2018 15:43 | pressemeddelelse
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk
BOEHRINGER-INGELHEIM22.6.2018 14:02 | pressemeddelelse
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center
TX-VIKING-ACQUISITION22.6.2018 13:11 | pressemeddelelse
Announcement by Viking Corp on Tecnotree
TX-HEARTSCIENCES22.6.2018 13:02 | pressemeddelelse
HeartSciences Named “Start-Up to Watch”
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum